These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 21476152

  • 1. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
    Cooper V, Moyle GJ, Fisher M, Reilly G, Ewan J, Liu HC, Horne R, SWEET (Simplification With Easier Emtricitabine Tenofovir) group, UK.
    AIDS Care; 2011 Jun; 23(6):705-13. PubMed ID: 21476152
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R, Herrera L, Moreno S.
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [Abstract] [Full Text] [Related]

  • 3. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
    DeJesus E, Ruane P, McDonald C, Garcia F, Sharma S, Corales R, Ravishankar J, Khanlou H, Shamblaw D, Ecker J, Ebrahimi R, Flaherty J, COMET Study Team.
    HIV Clin Trials; 2008 Feb; 9(2):103-14. PubMed ID: 18474495
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
    Arasteh K, Weitner L, Fenske S, Kuhlmann B, Freiwald M, Ebrahimi R, Gallo L, Ranneberg R, Mertenskoetter T.
    Eur J Med Res; 2009 May 14; 14(5):195-9. PubMed ID: 19541575
    [Abstract] [Full Text] [Related]

  • 8. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
    Cooper V, Horne R, Gellaitry G, Vrijens B, Lange AC, Fisher M, White D.
    J Acquir Immune Defic Syndr; 2010 Mar 14; 53(3):369-77. PubMed ID: 20087195
    [Abstract] [Full Text] [Related]

  • 9. Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
    Rosso R, Di Biagio A, Maggiolo F, Nulvesu L, Callegaro AP, Taramasso L, Bruzzone B, Viscoli C.
    AIDS Care; 2012 Mar 14; 24(1):54-8. PubMed ID: 21800951
    [Abstract] [Full Text] [Related]

  • 10. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
    Gianotti N, Galli L, Bocchiola B, Cahua T, Panzini P, Zandonà D, Salpietro S, Maillard M, Danise A, Pazzi A, Lazzarin A, Castagna A.
    HIV Med; 2013 Mar 14; 14(3):153-60. PubMed ID: 22994659
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M, Davis J, Langdon G, Layton G, Fang J, Choo HW, Hansson AG, Tawadrous M.
    Antivir Ther; 2013 Mar 14; 18(6):745-54. PubMed ID: 23558061
    [Abstract] [Full Text] [Related]

  • 13. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E, GESIDA 3903 Team.
    Clin Infect Dis; 2008 Oct 15; 47(8):1083-92. PubMed ID: 18781872
    [Abstract] [Full Text] [Related]

  • 14. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
    Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML.
    J Acquir Immune Defic Syndr; 2010 Sep 15; 55(1):49-57. PubMed ID: 20431394
    [Abstract] [Full Text] [Related]

  • 15. [Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
    Wepner U.
    MMW Fortschr Med; 2011 May 05; 153(18):20-1. PubMed ID: 21604586
    [No Abstract] [Full Text] [Related]

  • 16. [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1].
    Oyagüez I, Casado MA, Cotarelo M, Ramírez-Arellano A, Mallolas J.
    Farm Hosp; 2009 May 05; 33(5):247-56. PubMed ID: 19775575
    [Abstract] [Full Text] [Related]

  • 17. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.
    J Antimicrob Chemother; 2009 Dec 05; 64(6):1260-4. PubMed ID: 19776037
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM.
    Antivir Ther; 2013 Dec 05; 18(1):105-13. PubMed ID: 23043067
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
    Pujari S, Dravid A, Gupte N, Joshi K, Bele V.
    Medscape J Med; 2008 Dec 05; 10(8):196. PubMed ID: 18924648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.